{"id":"perindopril-arginine","rwe":[{"pmid":"41714068","year":"2026","title":"Perindopril: A comprehensive profile.","finding":"","journal":"Profiles of drug substances, excipients, and related methodology","studyType":"Clinical Study"},{"pmid":"39920745","year":"2025","title":"Application of spectrophotometry in novel simultaneous dissolution profiling of a single pill triple therapy of amlodipine, perindopril and indapamide; whiteness evaluation.","finding":"","journal":"BMC chemistry","studyType":"Clinical Study"},{"pmid":"39731708","year":"2025","title":"Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice.","finding":"","journal":"Advances in therapy","studyType":"Clinical Study"},{"pmid":"37341634","year":"2023","title":"Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.","finding":"","journal":"Journal of AOAC International","studyType":"Clinical Study"},{"pmid":"36544985","year":"2022","title":"COVID-19-induced myocarditis in patient with anomalous origin of the left circumflex artery from the right coronary artery: a case report.","finding":"","journal":"Jornal vascular brasileiro","studyType":"Clinical Study"}],"tags":[{"label":"Angiotensin Converting Enzyme Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Angiotensin-converting enzyme","category":"target"},{"label":"ACE","category":"gene"},{"label":"C09AA04","category":"atc"},{"label":"Oral","category":"route"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Hypertensive disorder","category":"indication"},{"label":"Myocardial Infarction Prevention","category":"indication"},{"label":"Symplmed Pharms Llc","category":"company"},{"label":"Approved 1990s","category":"decade"},{"label":"Angiotensin-Converting Enzyme Inhibitors","category":"pharmacology"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protease Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":545.625,"date":"","count":1699,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 1,699 times (LLR=546)"},{"llr":340.198,"date":"","count":725,"signal":"Hyponatraemia","source":"DrugCentral FAERS","actionTaken":"Reported 725 times (LLR=340)"},{"llr":301.161,"date":"","count":124,"signal":"Sensitisation","source":"DrugCentral FAERS","actionTaken":"Reported 124 times (LLR=301)"},{"llr":285.206,"date":"","count":127,"signal":"Polycystic ovaries","source":"DrugCentral FAERS","actionTaken":"Reported 127 times (LLR=285)"},{"llr":258.964,"date":"","count":494,"signal":"Hyperkalaemia","source":"DrugCentral FAERS","actionTaken":"Reported 494 times (LLR=259)"},{"llr":257.955,"date":"","count":101,"signal":"Ejection fraction","source":"DrugCentral FAERS","actionTaken":"Reported 101 times (LLR=258)"},{"llr":198.028,"date":"","count":22,"signal":"Systemic lupus erythematosus","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=198)"},{"llr":195.826,"date":"","count":328,"signal":"Lactic acidosis","source":"DrugCentral FAERS","actionTaken":"Reported 328 times (LLR=196)"},{"llr":192.446,"date":"","count":11,"signal":"Glossodynia","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=192)"},{"llr":189.914,"date":"","count":365,"signal":"Blood pressure systolic increased","source":"DrugCentral FAERS","actionTaken":"Reported 365 times (LLR=190)"},{"llr":188.197,"date":"","count":415,"signal":"Death","source":"DrugCentral FAERS","actionTaken":"Reported 415 times (LLR=188)"},{"llr":184.489,"date":"","count":726,"signal":"Blood pressure increased","source":"DrugCentral FAERS","actionTaken":"Reported 726 times (LLR=184)"},{"llr":183.801,"date":"","count":484,"signal":"Bradycardia","source":"DrugCentral FAERS","actionTaken":"Reported 484 times (LLR=184)"},{"llr":178.75,"date":"","count":18,"signal":"Pemphigus","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=179)"},{"llr":178.367,"date":"","count":33,"signal":"Completed suicide","source":"DrugCentral FAERS","actionTaken":"Reported 33 times (LLR=178)"}],"drugInteractions":[{"url":"/drug/spironolactone","drug":"spironolactone","action":"Monitor closely","effect":"May interact with Perindopril, Spironolactone","source":"DrugCentral","drugSlug":"spironolactone"},{"url":"/drug/triamterene","drug":"triamterene","action":"Monitor closely","effect":"May interact with Perindopril, Triamterene","source":"DrugCentral","drugSlug":"triamterene"}],"commonSideEffects":[{"effect":"Edema","drugRate":"7.2%","severity":"common","organSystem":""},{"effect":"Cough","drugRate":"3.2%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Dizziness","drugRate":"2.5%","severity":"common","organSystem":""},{"effect":"Hyperkalemia","drugRate":"2.4%","severity":"common","organSystem":""},{"effect":"Peripheral edema","drugRate":"1.8%","severity":"common","organSystem":""},{"effect":"Back pain","drugRate":"1.5%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"","severity":"common","organSystem":""},{"effect":"Rash","drugRate":"","severity":"common","organSystem":""}],"contraindications":["Acute cerebrovascular insufficiency","Angioedema","Bone marrow depression","Disease of liver","Disorder of connective tissue","Hereditary angioneurotic edema","Hyperkalemia","Kidney disease","Low blood pressure","Neutropenic disorder","Pregnancy, function","Renal artery stenosis"],"specialPopulations":{"Pregnancy":"Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. When pregnancy is detected, discontinue perindopril erbumine as soon as possible. These adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents. In the unusual case of pregnancy, appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. In the unusual case of pregnancy, appropriate management of maternal hypertension during pregnancy is important to optimize outcomes for both mother and fetus. Pregnancy Categories D. (See WARNINGS: Fetal/Neonatal Morbidity and Mortality).","Geriatric use":"The mean blood pressure effect of perindopril was somewhat smaller in patients over 60 than in younger patients, although the difference was not significant. Plasma concentrations of both perindopril and perindoprilat were increased in elderly patients compared to concentrations in younger patients. No adverse effects were clearly increased in older patients with the exception of dizziness and possibly rash. Perindopril should be used with caution when administered to elderly patients.","Paediatric use":"Safety and effectiveness of perindopril erbumine tablets in pediatric patients have not been established.","Renal impairment":"Dosage adjustment may be necessary in renally impaired patients."},"seriousAdverseEvents":[]},"trials":[],"aliases":[],"company":"Symplmed Pharms Llc","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2029-10-05","territory":"US","patentNumber":"7846961"},{"source":"FDA Orange Book via DrugCentral","expires":"2023-04-15","territory":"US","patentNumber":"6696481"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=PERINDOPRIL ARGININE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:20:07.270690+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:20:07.270612+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:20:12.186287+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PERINDOPRIL ARGININE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:20:12.549915+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Angiotensin-converting enzyme inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:14.020947+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3544986/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:20:13.520189+00:00"}},"allNames":"aceon","offLabel":[],"synonyms":["perindopril","perindopril erbumine","perindopril arginine"],"timeline":[{"date":"1993-12-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Symplmed Pharms Llc)"}],"brandName":"Aceon","ecosystem":[{"indication":"Hypertensive disorder","otherDrugs":[{"name":"acebutolol","slug":"acebutolol","company":"Promius Pharma"},{"name":"aliskiren","slug":"aliskiren","company":"Novartis"},{"name":"amiloride","slug":"amiloride","company":"Paddock Llc"},{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"}],"globalPrevalence":null},{"indication":"Myocardial Infarction Prevention","otherDrugs":[{"name":"amlodipine","slug":"amlodipine","company":"Pfizer"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"lovastatin","slug":"lovastatin","company":"Merck"},{"name":"pravastatin","slug":"pravastatin","company":"Bristol Myers Squibb"}],"globalPrevalence":523000000}],"mechanism":{"target":"Angiotensin-converting enzyme","novelty":"Follow-on","targets":[{"gene":"ACE","source":"DrugCentral","target":"Angiotensin-converting enzyme","protein":"Angiotensin-converting enzyme"}],"moaClass":"Angiotensin-converting Enzyme Inhibitors","modality":"Small Molecule","drugClass":"Angiotensin Converting Enzyme Inhibitor","explanation":"","oneSentence":"","technicalDetail":"Aceon inhibits the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing peripheral resistance and lowering blood pressure."},"commercial":{"launchDate":"1993","_launchSource":"DrugCentral (FDA 1993-12-30, SYMPLMED PHARMS LLC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2108","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=PERINDOPRIL%20ARGININE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PERINDOPRIL ARGININE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T02:40:00.825434","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:20:15.325653+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"captopril","drugSlug":"captopril","fdaApproval":"1981-04-06","genericCount":21,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"enalapril","drugSlug":"enalapril","fdaApproval":"1985-12-24","patentExpiry":"Nov 6, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lisinopril","drugSlug":"lisinopril","fdaApproval":"1987-12-29","patentExpiry":"Nov 6, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ramipril","drugSlug":"ramipril","fdaApproval":"1991-01-28","patentExpiry":"Aug 16, 2039","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"quinapril","drugSlug":"quinapril","fdaApproval":"1991-11-19","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"benazepril","drugSlug":"benazepril","fdaApproval":"1991-06-25","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fosinopril","drugSlug":"fosinopril","fdaApproval":"1991-05-16","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"trandolapril","drugSlug":"trandolapril","fdaApproval":"1996-04-26","genericCount":10,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"spirapril","drugSlug":"spirapril","fdaApproval":"1994-12-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"moexipril","drugSlug":"moexipril","fdaApproval":"1995-04-19","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"perindopril arginine","indications":{"approved":[{"name":"Hypertensive disorder","source":"DrugCentral","snomedId":38341003,"regulator":"FDA"},{"name":"Myocardial Infarction Prevention","source":"DrugCentral","snomedId":"","regulator":"FDA","usPrevalence":null,"globalPrevalence":523000000,"prevalenceMethod":"curated","prevalenceSource":"WHO CVD Factsheet, 2023"}],"offLabel":[{"name":"Atrial fibrillation","source":"DrugCentral","drugName":"PERINDOPRIL ARGININE","evidenceCount":0,"evidenceLevel":"emerging"},{"name":"Chronic heart failure","source":"DrugCentral","drugName":"PERINDOPRIL ARGININE","evidenceCount":8,"evidenceLevel":"emerging"},{"name":"Diabetic renal disease","source":"DrugCentral","drugName":"PERINDOPRIL ARGININE","evidenceCount":1,"evidenceLevel":"emerging"},{"name":"Diastolic heart failure","source":"DrugCentral","drugName":"PERINDOPRIL ARGININE","evidenceCount":3,"evidenceLevel":"emerging"},{"name":"Nondiabetic Proteinuric Nephropathy","source":"DrugCentral","drugName":"PERINDOPRIL ARGININE","evidenceCount":0,"evidenceLevel":"emerging"}],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"captopril","brandName":"captopril","genericName":"captopril","approvalYear":"1981","relationship":"same-class"},{"drugId":"enalapril","brandName":"enalapril","genericName":"enalapril","approvalYear":"1985","relationship":"same-class"},{"drugId":"lisinopril","brandName":"lisinopril","genericName":"lisinopril","approvalYear":"1987","relationship":"same-class"},{"drugId":"ramipril","brandName":"ramipril","genericName":"ramipril","approvalYear":"1991","relationship":"same-class"},{"drugId":"quinapril","brandName":"quinapril","genericName":"quinapril","approvalYear":"1991","relationship":"same-class"},{"drugId":"benazepril","brandName":"benazepril","genericName":"benazepril","approvalYear":"1991","relationship":"same-class"},{"drugId":"fosinopril","brandName":"fosinopril","genericName":"fosinopril","approvalYear":"1991","relationship":"same-class"},{"drugId":"trandolapril","brandName":"trandolapril","genericName":"trandolapril","approvalYear":"1996","relationship":"same-class"},{"drugId":"spirapril","brandName":"spirapril","genericName":"spirapril","approvalYear":"1994","relationship":"same-class"},{"drugId":"moexipril","brandName":"moexipril","genericName":"moexipril","approvalYear":"1995","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04040634","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-08","conditions":["Diabetes Mellitus","High Blood Pressure","Cardiovascular Diseases","Cognitive Impairment"],"enrollment":9476,"completionDate":"2026-05-31"},{"nctId":"NCT05288400","phase":"PHASE3","title":"Evaluation of the Clinical Efficacy and Safety of Amlodipine 5mg/ Bisoprolol Fumarate 5mg /Perindopril Arginine 5mg Fixed-dose Combination in Capsule and Free Monotherapy at the Same Dose in Patients With Uncontrolled Essential Hypertension.","status":"COMPLETED","sponsor":"Servier","startDate":"2018-05-14","conditions":["Essential Hypertension"],"enrollment":150,"completionDate":"2018-12-18"},{"nctId":"NCT06704815","phase":"","title":"Observational Cohort Study Evaluating the Effectiveness of an Educational Program (NGAYDAUTIEN) in Combination With Perindopril and Amlodipine Single-Pill Combination in Hypertensive Patients naïve of Antihypertensive Treatments.","status":"COMPLETED","sponsor":"Servier Affaires Médicales","startDate":"2023-01-31","conditions":["Hypertension"],"enrollment":400,"completionDate":"2024-06-12"},{"nctId":"NCT05764317","phase":"","title":"Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2023-04-30","conditions":["Arterial Hypertension","HTN"],"enrollment":409,"completionDate":"2024-02-20"},{"nctId":"NCT06213610","phase":"PHASE1","title":"Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2024-01-09","conditions":["Bioequivalence"],"enrollment":50,"completionDate":"2024-06-01"},{"nctId":"NCT04036409","phase":"NA","title":"Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients","status":"UNKNOWN","sponsor":"Hospital Israelita Albert Einstein","startDate":"2019-08-05","conditions":["Ischemic Stroke","Blood Pressure","Cognitive Impairment","Vascular Diseases"],"enrollment":4369,"completionDate":"2025-12"},{"nctId":"NCT04591808","phase":"PHASE3","title":"Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia","status":"TERMINATED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2021-09-09","conditions":["Dyslipidemias","Hypertension"],"enrollment":146,"completionDate":"2022-04-08"},{"nctId":"NCT05940909","phase":"PHASE1","title":"Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting Conditions","status":"UNKNOWN","sponsor":"Pharmtechnology LLC","startDate":"2023-06-24","conditions":["Bioequivalence"],"enrollment":50,"completionDate":"2023-11-17"},{"nctId":"NCT05470764","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-Butylamine / 2.5 mg Indapamide / 10 mg Amlodipine Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide / 10 mg Amlodipine Film-Coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-30","conditions":["Bioequivalence","Healthy Subjects"],"enrollment":52,"completionDate":"2021-06-28"},{"nctId":"NCT05464745","phase":"PHASE1","title":"Bioequivalence Study of 8 mg Perindopril Tert-butylamine / 2.5 mg Indapamide Tablets Versus 10 mg Perindopril Arginine / 2.5 mg Indapamide Film-coated Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Darnitsa Pharmaceutical Company","startDate":"2021-05-19","conditions":["Bioequivalence","Healthy Subjects"],"enrollment":42,"completionDate":"2021-06-09"},{"nctId":"NCT03722524","phase":"","title":"The Use of TrIple Fixed-dose Combination in the Treatment of Arterial Hypertension","status":"COMPLETED","sponsor":"Servier Russia","startDate":"2018-10-01","conditions":["Arterial Hypertension"],"enrollment":1247,"completionDate":"2019-07-17"},{"nctId":"NCT01118520","phase":"PHASE2","title":"AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2011-09","conditions":["Abdominal Aortic Aneurysm"],"enrollment":224,"completionDate":"2015-04"},{"nctId":"NCT04254042","phase":"PHASE4","title":"Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2018-10-01","conditions":["Hypertension"],"enrollment":24,"completionDate":"2019-05-01"},{"nctId":"NCT04222686","phase":"PHASE4","title":"Evaluation of Losartan and Perindopril in Blacks Type 2 Diabetics Patients","status":"COMPLETED","sponsor":"Yaounde Central Hospital","startDate":"2017-12-20","conditions":["Type 2 Diabetes Mellitus"],"enrollment":23,"completionDate":"2018-04-30"},{"nctId":"NCT01556997","phase":"PHASE3","title":"Perindopril Amlodipine for the Treatment of Hypertension","status":"COMPLETED","sponsor":"Symplmed Pharmaceuticals LLC","startDate":"2012-02","conditions":["Essential Hypertension"],"enrollment":837,"completionDate":"2013-02"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Tablet","formulations":[{"form":"TABLET","route":"ORAL","productName":"Perindopril Erbumine"},{"form":"TABLET","route":"ORAL","productName":"Aceon"},{"form":"TABLET","route":"ORAL","productName":"Perindopril Erbumine"},{"form":"TABLET","route":"ORAL","productName":"Prestalia"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000148627","MMSL":"169198","NDDF":"004018","UNII":"Y5GMK36KGY","VUID":"4021179","CHEBI":"CHEBI:8024","VANDF":"4021179","INN_ID":"5754","RXNORM":"1546400","UMLSCUI":"C0136123","chemblId":"CHEMBL3544986","ChEMBL_ID":"CHEMBL1581","KEGG_DRUG":"D00624","DRUGBANK_ID":"DB00790","PDB_CHEM_ID":" X94","PUBCHEM_CID":"107807","SNOMEDCT_US":"129485000","IUPHAR_LIGAND_ID":"6367","SECONDARY_CAS_RN":"107133-36-8","MESH_DESCRIPTOR_UI":"D020913","MESH_SUPPLEMENTAL_RECORD_UI":"C053500"},"formularyStatus":[],"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"1993-","companyName":"Symplmed Pharms Llc","relationship":"Original Developer"}],"pharmacokinetics":{"source":"FDA label","halfLife":"10 hours","bioavailability":"25%","fractionUnbound":"0.312%"},"publicationCount":61,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C09AA04","allCodes":["C09AA04","C09BA04","C09BB04","C09BX01","C09BX02","C09BX04","C10BX11","C10BX12","C10BX13","C10BX14","C10BX15"]},"biosimilarFilings":[],"originalDeveloper":"Symplmed Pharms Llc","recentPublications":[{"date":"2026","pmid":"41714068","title":"Perindopril: A comprehensive profile.","journal":"Profiles of drug substances, excipients, and related methodology"},{"date":"2025 Feb 7","pmid":"39920745","title":"Application of spectrophotometry in novel simultaneous dissolution profiling of a single pill triple therapy of amlodipine, perindopril and indapamide; whiteness evaluation.","journal":"BMC chemistry"},{"date":"2025 Feb","pmid":"39731708","title":"Simplified Approach to Managing Newly Diagnosed Patients with Mild-to-Moderate Hypertension in Routine Clinical Practice.","journal":"Advances in therapy"},{"date":"2023 Sep 1","pmid":"37341634","title":"Chromatographic Techniques for Assessment of Bisoprolol Fumarate and Perindopril Arginine in Solid Formulations under Various Stress Conditions and Application to Six Sigma, Content Uniformity, and Comparative Dissolution Approaches.","journal":"Journal of AOAC International"},{"date":"2022","pmid":"36544985","title":"COVID-19-induced myocarditis in patient with anomalous origin of the left circumflex artery from the right coronary artery: a case report.","journal":"Jornal vascular brasileiro"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Symplmed Pharms Llc","companyId":"symplmed-pharms-llc","modality":"Small molecule","firstApprovalDate":"1993","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"6696481","territory":"US","patent_type":null,"expiry_date":"2023-04-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7846961","territory":"US","patent_type":null,"expiry_date":"2029-10-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:20:15.325653+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}